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Discussion and Future Perspectives
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Avoidance of potential DDIs is a clinically relevant issue when trying to improve the quality of drug 
prescribing since DDI can inadvertently lead to therapeutic failures or toxicities. In the Netherlands, 
to prevent DDI induced ADR, the electronic prescription system is complemented with a DDI 
surveillance tool which works during drug prescription and before drug dispensing to monitor 
a potential DDI. The resulting computerized DDI alerts are evidence-based and regularly updated 
by the distributors of the Z-index (publisher of the G-standard and partner of KNMP-The Hague 
NL) and the Health Base Foundation (publisher of Pharmabase and partner of Pharma Partners, 
Oosterhout, NL)1. The application of DDI alerting systems has been reported to increase patient 
safety, improve prescribing practice, and decrease healthcare spendings2.  In contrast, some 
studies reported that warnings provided by the DDI alerts are often ignored either by physicians 
or pharmacists2,3. There are many reasons for such overriding behavior including excessive alerts, 
the fact that benefit outweighs risk, disapproval of patients to treatment modification, confidence 
of prescribing clinicians on their knowledge regarding a specific DDI, impractical recommendations 
provided by the systems, disagreement with other DDI compendia, complicated technologies, 
interruptions of working process, patients previously tolerating adverse reactions resulting 
from DDI, and unclear clinical relevance2,4-6. The absence of certainty around clinical relevance 
may be because the assessment of various potential DDIs rely on theoretical considerations and 
extrapolations of one reported case of an interaction to other drugs within the same therapeutic 
class2. Moreover, some potential DDIs are only supported by low quality of causal evidence (in vitro 
studies or a case report) and lack of well-designed studies with control groups to support decision 
making in handling the potential DDIs7. Hence, the need to identify and to estimate the burden of 
such DDIs as well as to assess their potential clinical implication is high in order to further improve 
the quality of the DDI alerts and DDIs managements.
Burden and Management of DDI
In chapter 2, we estimated the frequency of potential DDIs ignored by the health practitioners 
using a cross-sectional study in the Dutch three-generation population Lifelines cohort as part 
of the PharmLines Initiative. Since the medication data in the Lifelines cohort were collected by 
using self-reported questionnaires, there was a need to validate the potential DDI information by 
using the University of Groningen prescription database IADB.nl as a reference tool before being 
used in a pharmacoepidemiological study. We found that one to two per hundred drug users in 
the Lifelines cohort were exposed to a potential CYP2D6/2C19/2C9-mediated DDI at least in a short 
period in time during entry of the cohort study. The concordance analysis between the Lifelines 
cohort and the prescription database IADB.nl on the combination of substrates and inhibitors of 
CYP2D6/2C19/2C9 indicated that the best concordance level was achieved using a time window of 
three months which agrees with previous validation studies8,9. Further analysis based on the type of 
interacting medication showed that self-reported information on the combination of two regularly 
used drugs were more reliable (good agreement) than the combination of drugs used routinely 
and episodically (fair to moderate agreement). However, the latter was still more reliable than 




Among the most commonly presented potential DDIs were co-prescriptions of metoprolol 
(a CYP2D6 substrate) with strong CYP2D6 inhibitors such as paroxetine and fluoxetine. 
The combination is likely observed in clinical practice because cardiovascular and psychiatric 
diseases are frequent comorbid diseases10. Therefore, in chapter 3, we further analyzed the burden of 
these potential DDIs among the high-risk senior population. We found that despite the application 
of the DDI alerting systems, metoprolol-paroxetine/fluoxetine combinations were still commonly 
co-prescribed (2039 incidences)5. The contradictory assessment of two main knowledge-bases of 
the Dutch DDI alerts about the clinical impact of the DDIs might be the culprit5. We also found that 
switching either metoprolol or paroxetine/fluoxetine to other safer drugs was uncommon practice5. 
Moreover, in this elderly group, the dose of metoprolol prescription is generally low, regardless its 
combination with paroxetine/fluoxetine5. 
Using this information, we designed an observational retrospective cohort study to investigate 
the potential impact of metoprolol-paroxetine/fluoxetine combination among senior persons using 
the IADB.nl with two proxy parameters i.e. early termination or dose modification of metoprolol 
after the initiation of paroxetine/fluoxetine on metoprolol prescriptions (chapter 4). Compared 
to metoprolol-citalopram (which is a weak CYP2D6 inhibitor) co-prescription, the metoprolol-
paroxetine/fluoxetine combination was not significantly associated with the need of early 
termination and a dose modification of metoprolol in elderly11. However, if the combination was 
compared with metoprolol-mirtazapine (which has no inhibitory capacity on CYP2D6) combination, 
metoprolol-paroxetine/fluoxetine co-prescription was significantly associated with the need 
of early termination but not a dose modification of metoprolol, especially in the subgroup of 
female older persons11. Therefore, it seems that the prescribing doctors prefer stopping over dose 
modification of metoprolol when there is a sign of metoprolol related toxicities.
By compiling and screening all studies related to the impact of metoprolol-paroxetine/
fluoxetine combinations, we systematically evaluated the clinical relevance of this DDI (chapter 5). 
We found three case reports, four experimental and two observational studies that reported on 
the clinical outcomes of the DDI12. Though not all studies agreed on the clinical impact, the majority 
of the studies reported that the DDI may have potentially deleterious impacts12. Therefore, 
avoiding the DDI should be considered because alternative safe combinations of beta-blockers 
and antidepressants with comparable effectiveness are available. However, if the combination is 
necessary, dose reduction of metoprolol as well as close monitoring of the metoprolol related 
side effects is crucial especially in the high risk population12.  A relevant limitation of the included 
studies was that they did not consider patients’ CYP2D6 phenotype status which can potentially 
modify the clinical severity of the DDI12. CYP2D6 has an essential role to metabolize metoprolol 
and therefore, the phenotype status of CYP2D6 is essential13. The magnitude of metoprolol-
paroxetine/fluoxetine interaction on patients with deviating phenotypes might be different than in 
the population with the normal phenotype. A study from Goryachkina et al. indicated that among 
acute myocardial infarction patients using metoprolol and starting paroxetine 20 mg (n=17), two 
patients, who were CYP2D6 intermediate metabolizers (IM), required a dose modification because 
of the appearance of metoprolol related side effects such as postural hypotension and excessive 
bradycardia14. Phenoconversion was most likely responsible for these side effects since paroxetine 
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may change the phenotype status of CYP2D6 from IM to be poor metabolizer (PM). It was reported 
that persons with only one active allele are more easily phenoconverted to become PM than those 
with at least two functional genes (NM)15. This illustrates that the severity of the DDI depends on 
the catalytic activity of the main metabolic enzymes.
Pharmacogenetics of drug interactions
We further reviewed systematically the impact of polymorphisms on three main drug metabolic 
enzymes (CYP2D6, CYP2C19, and CYP2C9) mediated DDIs and drug-drug-gene-interactions 
(DDGIs) (chapter 6). The clinical impact of a CYP-mediated pharmacokinetic DDI is greatly affected 
by the genetic status of this metabolic enzyme16. The greater the role of CYP catalytic activity to 
the substrate disposition, the stronger the magnitude of DDI that might be exerted by an inhibitor 
drug. Therefore, the extent of the DDI magnitude can mostly be explained following the sequence 
of NM > IM > PM16. 
Furthermore, a more complex interaction is obtained when there is an interplay of gene 
polymorphism and a perpetrator drug (DDGI) in affecting the metabolism of a substrate16. DDGI 
may involve the disposition of a drug metabolized with multiple pathways by multiple impairment 
schemes due to a non-active allele and an inhibitor. The obstruction of one biotransformation 
pathway by an allelic polymorphism makes the role of the secondary elimination pathway more 
important than in the normal condition. Hence, the subsequent alteration of the minor metabolic 
pathway by an inhibitor may produce a substantial increase of substrate blood concentration and 
generate a more severe interaction than the expected DDI. It can be seen in a case report which 
recorded an opioid toxicity in a hydrocodone (a CYP2D6 and CYP3A4 substrate) treated child with 
a decreased function of CYP2D6 who was co-administered clarithromycin (a CYP3A4 inhibitor)17. 
The decreased metabolic activity of CYP2D6 due to genetic polymorphism makes the metabolic 
contribution of CYP3A4 becomes more important. Consequently, the addition of clarithromycin 
further impaired the biodegradation of hydrocodone. As a result, a very high concentration of 
hydrocodone led to the hydrocodone toxicity in the child.
The magnitude of DDGI also depends on the number of functional CYP alleles. PM and IM produce 
a greater extent of DDGI than NM because the less the contribution of main metabolic pathway, 
the greater the metabolic contribution of the secondary pathway. It can be seen in the interaction 
between voriconazole (a CYP2C19/3A4 inhibitor and substrate) and tacrolimus (a CYP2C19 and 
CYP3A4/5 substrate)  in different CYP2C19 genotypes18. Voriconazole increased the AUC values of 
tacrolimus by 4.4, 6, 6.5-fold in patients with CYP2C19 NM, IM, and PM, respectively, compared to 
patients with CYP2C19 NM using tacrolimus alone. In NM, the inhibition of CYP3A4 by voriconazole 
is less because tacrolimus metabolism via CYP2C19 is intact as well as voriconazole is also 
metabolized effectively by CYP2C19. However, a decreased metabolic function in CYP2C19 IM and 
PM lead to a more pronounced metabolic role of CYP3A4 in the disposition of tacrolimus. Moreover, 
the magnitude of the voriconazole AUC is also higher in CYP2C19 IM and PM than NM which leads to 
a stronger CYP3A4 inhibition in CYP2C19 IM and PM. As a consequence, the tacrolimus AUC is also 
substantially higher in PM and IM than NM. Hence, polymorphism has a pivotal role in determining 




We then explored the influence of genetic polymorphisms and drug interactions using real-
world-data. In chapter 7, we presented an inception cohort study about the associations between DGI, 
DDI and DDGI to (es)citaloporam therapy. We found that patients with predicted reduced metabolic 
function of CYP2C19 had a higher risk of switching and/or dose reduction of (es)citalopram than 
those with normal metabolic function. Additionally, CYP3A4 with predicted reduced-function-allele 
seemed to potentiate the effect sizes. Yet, in the condition of CYP2C19 NM, CYP3A4 with predicted 
decreased metabolic function seemed not to have an important effect on (es)citalopram treatment. 
Fudio et al. reported a comparable trend of outcomes for CYP2D619. CYP2D6 with reduced-function-
allele has a limited impact on (es)citalopram metabolism when CYP2C19 has normal catalytic 
activity. However, it may increase the effects of decreased metabolic function of CYP2C19 on (es)
citralopram disposition. It might imply that it is important to know pre-emptively the predicted 
phenotype status of not only CYP2C19 but also CYP3A4 and CYP2D6. Within our relatively limited 
sample size (316 patients), we found that more than half of them had a deviating genotype related 
drug interaction either in the form of DGI or DDGI. These high numbers were probably unnoticed 
by clinicians since they had no information about the genetic status of the patients at the time of 
(es)citalopram prescription. Consequently, it might potentially pose considerable health impact as 
well as economic burden. Therefore, it is important to have information of the genetics status of 
multiple enzymes involved in drug disposition at the time of prescription.
Future perspectives and need for research
The magnitude of drug interactions is determined by the contribution of intrinsic and extrinsic 
factors. Significant alteration of these factors might lead to changes in the clinical implication 
of drug interactions. Yet, current guidelines to manage drug interactions have not considered 
the concurrent influence of the intrinsic and extrinsic factors, which potentially produces complex 
drug interactions, on the severity and management of drug interactions.
In our research, we directed our focus on the contribution of the three main phase I drug 
metabolizing enzymes. Yet, drug interactions might also be facilitated by phase II drug metabolizing 
enzymes and drug transporters which are also subjects to genetic polymorphisms20,21. Drug 
interactions might be influenced by multiple pharmacogenes involving both genes related to drug 
metabolizing enzymes and transporters simultaneously22. Furthermore, genetic polymorphisms 
can also change the pharmacodynamic response of a drug. Polymorphisms on drug targets might 
influence the severity or even direction of drug responses23. However, drug interaction studies 
rarely consider simultaneous contributions of pharmacogenes related to pharmacokinetics and 
pharmacodynamics of drug in assessing the impact of particular drug interactions. Consequently, 
the knowledge about combined contribution of these gene variants on the impact of drug 
interactions is still limited and requires more scientific explorations.
Another important intrinsic factor that may affect the pharmacokinetics of drugs is the disease 
itself, either as the main disease or as a comorbidity. Diseases such as kidney failure, liver diseases, 
metastatic cancer or chronic inflammation have been reported to modify the magnitude of drug 
interactions24. In clinical practice, the information about patients’ diseases are commonly available 
and considered at the time of prescription. However, together with a perpetrator drug and genetic 
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polymorphism, these diseases may generate complex drug-drug-gene-disease interactions (DDGDI) 
which may produce a wide range of inter-individual variability on drug exposures24. The clinical 
manifestation of DDGDI can be illustrated in an opioid intoxication report because of the use of 
clarithromycin and voriconazole (CYP3A4 inhibitors) by a 62-year-old CYP2D6 UM patient with 
acute renal failure who was treated with codeine (a CYP2D6 and CYP3A4 substrate)25. The inhibition 
of CYP3A4 makes the CYP2D6 the only available metabolic pathway of codeine. However, because of 
the gene duplication, CYP2D6 has an increased capacity to convert codeine to morphine. The blood 
concentration of morphine was then increased about 20 to 80 fold compared to the expected range. 
Moreover, the patient also had a decreased renal function. Therefore, the excretion of glucuronide 
metabolites of morphine was impaired and led to their accumulation. Morphine-3-glucuronide and 
morphine-6-glucuronide are also active metabolites and have opioid activities. As a consequence, 
the patient developed coma and respiratory depression25. A comprehensive review about DDGDI 
can be read elsewhere24.
In order to achieve personalized management of drug interactions, clinical predictors covering 
genetic and non-genetic factors potentially influencing the magnitude of drug interactions 
should be identified and their contributions should be quantified as well as validated. Once those 
factors can be elucidated, they can be incorporated in a modelling and biosimulation study such 
as physiologically based pharmacokinetic (PBPK) in order to predict their combined effects on 
drug pharmacokinetics quantitatively26. This method may accommodate a lot of information which 
may influence drug pharmacokinetics such as drug related aspects and variation in physiological 
properties of the individual patient26,27. Such a model can give guidance to providing clinical dosing 
recommendation for individuals exposed to complex drug interactions27. PBPK have been shown to 
successfully estimate the impact of CYP2D6 mediated DDGI and therefore, can be exercised in other 
clinical schemes28. 
Moreover, for routine implementation, multiple genes testing using panel-based 
pharmacogenomics should be done prospectively and the genetic status of the pharmacogenes 
should be incorporated in the electronic health records of patients. Nonetheless, despite increasing 
published evidence reporting the importance of pharmacogenetics guided pharmacotherapy, 
some reports indicated that this personalized concept of medication is still infrequently adopted by 
clinicians29,30. Costs of pharmacogenomic testing and lack of knowledge are among the most cited 
barriers hindering the implementation by clinicians31,32.
The coverage of pharmacogenetic testing costs by health insurance companies is still limited 
to several genes related to adverse drug reactions. Since the current evidence is still composed 
of small studies with limited samples, large randomized clinical trials with the aim to investigate 
the clinical utility and cost-effectiveness of preemptive implementation of panel-based screening 
for selected multiple relevant pharmacogenes in a particular age group (elderly) or condition 
(kidney failure) are needed30,33,34. The restriction to a particular group of genes and a high risk 
population might help to improve the value of a pre-emptive pharmacogene testing strategy, and 
therefore might boost its implementation, in case of scarcity in the available healthcare budget35. 
Therefore, the pharmacogenes panel should be quite flexible to allow additional genetic variants if 




Furthermore, awareness and knowledge of health care practitioners about internal and external 
factors as well as their interactions which might influence the severity of drug interactions need to 
improve. The teaching and training subject of drug interaction should be expanded to include not 
only the mechanisms, clinical relevance and management of bimodal drug interactions such as DDI 
or DGI, but also complex drug interactions such as DDGI and DDGDI. 
Since patients often carry multiple actionable pharmacogenes and the trend of 
polypharmacotherapy is increasing especially in elderly population with multiple diseases, 
clinicians are very likely to encounter either DDI, DGI, DDGI or DDGDI in healthcare facilities. 
The multimodal drug interactions are preventable when the computerized surveillance system can 
be used to predict these incidences. Yet, current management of DDIs with DDI alerts is still limited 
to only handle a binary drug interaction and lacks the ability to detect or manage complex drug 
interactions. Therefore, the DDI alerts incorporated in computerized physician order entry should 
be improved to be able to screen and combine all information about potential factors influencing 
the impact of drug interactions such as multi-prescriptions from different health care facilities as 
well as non-prescribed drugs, genetics, comorbidities, laboratory data (kidney or hepatic function), 
life style (smoking, drinking alcohol), or patient specific information (allergy, pregnancy, age, sex, 
BMI)2. The drug interaction clinical decision support should have an advanced ability to produce 
clinical information about the severity of drug interactions as well as to provide case specific 
recommendations according to potential drug interaction risks. Nevertheless, more research 
is still required to provide sufficient evidence which can be used to assess clinical relevance of 
complex drug interactions and to support the development of guidelines on practical management 
of the complex interactions. Big databases which cover information about the clinical data and 
genetic information of patients, their medication, as well as treatment outcomes offer possibility 
to study the clinical impact of the complex interaction. The outcomes of the research should be 
then incorporated into the knowledge-bases of the DDI alerts to support the implementation of 
personalized management of drug interactions.
To conclude, in our work we showed that potential DDIs might still happen in daily clinical practice 
despite the use of the DDI alerting systems. To further improve medication safety, assessments of 
the clinical relevance of these potential DDIs is essential notably for older and vulnerable patients. 
Scientific explorations should consider the genetic background of the patient since polymorphisms 
in drug-metabolizing enzymes could substantially modify the outcome severity of DDIs. Even 
more, if a genetic polymorphism and an effector drug co-occur this may result in a complex DDGI 
responsible for a greater inter-individual variability in the magnitude of interactions than bimodal 
DDI or DGI. Consequently, generalizations made in pharmacotherapeutical management of drug 
interactions in clinical practice may be inappropriate. In the near future, pharmacogenomics 
will therefore become a fundamental backbone to support the implementation of personalized 
management of drug interactions.
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